Neuronetics, Inc.
Neuronetics, Inc. is a publicly traded medical technology company that develops and markets the NeuroStar Advanced Therapy System, an FDA-cleared transcranial magnetic stimulation platform for treating major depressive disorder, OCD, anxious depression, and adolescent depression, sold to U.S. psychiatry and mental health practices.
- Company typePublic
- Founded-
- HeadquartersMalvern, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neuronetics, Inc. does
Neuronetics, Inc. is a publicly traded medical technology company headquartered in Malvern, Pennsylvania, that designs, develops, and markets the NeuroStar Advanced Therapy System for transcranial magnetic stimulation (TMS) treatment. The NeuroStar system uses focused magnetic pulses to stimulate underactive neurons in brain regions controlling mood, offering a non-invasive, non-drug outpatient alternative for adults with major depressive disorder (MDD) who have not achieved satisfactory improvement from antidepressant medications. The platform is FDA-cleared for MDD, obsessive-compulsive disorder (OCD), anxious depression, and adolescent depression (ages 15-21), and has been the U.S. market leader in TMS therapy for over 12 years.
The technology platform comprises proprietary hardware including the patented Precision Pulse coil design (optimized to preferentially stimulate cortical neurons rather than sensory neurons) and the SenStar Treatment Link for dose verification, paired with proprietary software including MT Assist for motor threshold determination, TrakStar (a HIPAA-compliant cloud-based patient data management system spanning up to five connected systems), Contact Sensing for real-time 3D dose feedback, and the TouchStar Theta Burst protocol that reduces treatment sessions to approximately 3 minutes. The system also incorporates D-Tect, FastMT, and MT Cap innovations to reduce motor threshold setup time. Neuronetics operates the world's largest depression Outcomes Registry, with data on over 17,700 patients across 118 practice sites since 2016, supplemented by 65+ investigator-initiated clinical studies covering 1,900+ patients.
Neuronetics generates revenue primarily through direct sales of TMS systems to U.S. healthcare practices—over 1,100 active treatment locations—using an enterprise field sales motion complemented by inside-sales customer support and a 5 STARS Solution program that helps practices operationalize and grow TMS service lines. Practices then bill insurance for treatment sessions, with reimbursement available through Medicare, Tricare, and over 95 major U.S. commercial insurers covering approximately 300 million lives; the average 5 STARS practice generates over $300,000 in treatment revenue. International expansion is conducted through regional distributors in Japan (TEIJIN PHARMA), South Korea (DK Healthcare), the UAE (BDH Middle East), and Singapore/Hong Kong (Transmedic). The company employs approximately 215 people, including 100+ field experts across sales, training, reimbursement, and service functions.
Neuronetics, Inc. firmographics
Firmographics- Name
- Neuronetics, Inc.
- Legal name
- Neuronetics, Inc.
- Website
- https://neurostar.com
- Company type
- Public
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Neuronetics, Inc. is a publicly traded medical technology company that develops and markets the NeuroStar Advanced Therapy System, an FDA-cleared transcranial magnetic stimulation platform for treating major depressive disorder, OCD, anxious depression, and adolescent depression, sold to U.S. psychiatry and mental health practices.
- Ownership category
- akta.pro rank
Neuronetics, Inc. industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
Keywords
Where Neuronetics, Inc. is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Neuronetics, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Marketing or Sales, Personnel, Technology or R&D, Operations, Supply Chain
Revenue model
- NeuroStar TMS Device/System Sales: NeuroStar sells TMS systems to healthcare practices. Practices then bill insurance (Medicare, Tricare, commercial insurers) for treatment sessions. The company provides practice support including training, marketing, and reimbursement assistance.
- Treatment Services Reimbursement: Healthcare practices perform treatments and bill insurance. Over 300 million people have insurance plans covering NeuroStar. Medicare provides 100% coverage (61 million covered). Over 95 major U.S. private insurers provide coverage.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Treatment reimbursement varies by insurer and plan |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Neuronetics, Inc. product offering
Product offeringCore offering
Neuronetics designs, manufactures, and markets the NeuroStar Advanced Therapy System, an FDA-cleared transcranial magnetic stimulation (TMS) platform that uses focused magnetic pulses to stimulate underactive neurons in mood-regulating regions of the brain. The system is sold to healthcare practices (psychiatry practices and mental health clinics) for treatment of Major Depressive Disorder in adults and adolescents (ages 15-21), OCD, and anxious depression. The company supports practices through its 5 STARS Solution program, providing implementation, training, marketing, and reimbursement assistance.
Product overview
Neuronetics, Inc. offers the NeuroStar Advanced Therapy System as its primary product—a unified TMS (transcranial magnetic stimulation) platform for treating depression and related conditions. The system consists of proprietary hardware components (SenStar Treatment Link, Precision Pulse coil) and software modules (MT Assist for dose determination, TrakStar for patient data management, Contact Sensing for real-time monitoring). Newer features include TouchStar Theta Burst protocol for faster treatments (~3 minutes) and tools like FastMT, D-Tect, and MT Cap for efficient Motor Threshold determination. The platform supports multiple indications including MDD, OCD, and anxious depression, with different versions for U.S. and international markets.
Differentiator
Problem solved
Functional benefit
Brands
- SenStar Treatment Link: Treatment coil interface ensuring proper functioning and positioning during treatment sessions
- MT Assist
- Precision Pulse TMS
- Coil Positioning System
- TMS TrakStar
- TouchStar Theta Burst
- D-Tect
- FastMT
- MT Cap
Products and services
- NeuroStar Advanced Therapy System FDA-cleared transcranial magnetic stimulation (TMS) system for treating Major Depressive Disorder, OCD, and anxious depression in adults and adolescents ages 15-21, using focused magnetic pulses to stimulate underactive brain regions. Includes proprietary components (SenStar Treatment Link, Precision Pulse coil, Coil Positioning System), software (MT Assist, TMS TrakStar) and protocols (TouchStar Theta Burst, Contact Sensing, FastMT, D-Tect, MT Cap). Sold to healthcare practices including psychiatry practices and mental health clinics; available internationally through regional distributors.
Quantifiable outcome
- 83% response rate and 62% remission rate by clinician rating in acute treatment course
- +6 more outcomes
Companies that use Neuronetics, Inc.
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles2 records
Neuronetics, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Neuronetics, Inc. partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered regional.
- TEIJIN PHARMA LIMITEDregionalJapan distributor for NeuroStar TMS Therapy. Located at Kasumigaseki Common Gate West Tower, 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-8585, Japan. Handles distribution and support for Japanese market.
- DK HealthcareregionalSouth Korea distributor for NeuroStar TMS Therapy. Located at 4 Fl DK+ Bldg, 18, Baumoe-ro 7 gil, Seocho-gu, Seoul, South Korea 06762. Phone: +82 (2) 529-0155. Handles distribution and support for Korean market.
- BDH Middle EastregionalMiddle East distributor (UAE) for NeuroStar TMS Therapy. Contact: Mr. Noveel Pandya, Umm Ramool, Rashidiya, Dubai, UAE. Phone: +971 (42) 85-2211. Handles distribution and support for Middle East market.
- Transmedic Pte LtdregionalSoutheast Asia distributor (Hong Kong and Singapore) for NeuroStar TMS Therapy. Contact: Mr Darren Por, 5 Jalan Kilang Barat, 9/F Petro Centre, Singapore 159349. Phone: +65 6737-1945. Handles distribution and support for Southeast Asian markets.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Neuronetics, Inc. competitors and assessment
Company assessmentDirect peers
- MagVenture: Danish manufacturer of TMS equipment (MagPro) used by psychiatrists and researchers for depression and clinical neuroscience. Competes head-to-head with NeuroStar in TMS system sales to psychiatric practices and clinical research centers.
- Magstim: U.K.-based manufacturer of transcranial magnetic stimulation systems used in clinical research and psychiatric treatment. Sells TMS equipment to neuroscience and psychiatry practices globally, overlapping directly with NeuroStar's installed-base customers.
- Brainsway: Israel-based medical device company that develops and markets Deep TMS systems for major depressive disorder and OCD. Directly competes with NeuroStar in the U.S. TMS equipment market, targeting the same psychiatrist customer base with a similar FDA-cleared indication profile.
Broad incumbents
- Axsome Therapeutics: Commercial CNS biopharmaceutical company with FDA-approved therapies for major depressive disorder (e.g., Auvelity). Competes with NeuroStar for treatment-resistant depression patients and psychiatrist prescribing, but via a pharmaceutical rather than device mechanism.
- Janssen Pharmaceuticals (Johnson & Johnson) — Spravato: Markets esketamine (Spravato) nasal spray for treatment-resistant depression. Targets the same psychiatrist channel and patient population as NeuroStar, representing a major non-device alternative for the TRD segment.
- Sage Therapeutics: CNS biopharmaceutical company developing therapies for depression and other neuropsychiatric conditions. Competes for the same treatment-resistant MDD patient pool as NeuroStar, though through a pharma rather than neuromodulation approach.
Emerging players
- Compass Pathways: Clinical-stage mental health care company developing psychedelic therapies for treatment-resistant depression. Represents a future alternative treatment paradigm that could compete with TMS for the same TRD patients and specialist prescribing capacity.
- Neurosoft Bioelectronics: Developer of transcranial magnetic stimulation technologies for psychiatric and neurological disorders. Competes at the equipment layer with NeuroStar but is earlier-stage and smaller in installed base.
- Fisher Wallace: Markets consumer-grade cranial electrical stimulation devices marketed for depression, insomnia, and anxiety. Overlaps with NeuroStar in 'non-drug depression treatment' demand but addresses a much earlier-stage, patient-direct channel.
Others
- Somatics LLC: Manufacturer of ECT (electroconvulsive therapy) devices used in severe, treatment-resistant depression. Targets a smaller subset of the same psychiatrist channel as NeuroStar and is sometimes referenced as a fallback for patients who do not respond to TMS.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neuronetics, Inc. social profiles
Digital presenceNeuronetics, Inc. compliance and trust
Trust signalCompliance1 record
Neuronetics, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neuronetics, Inc. leadership team
Management profileNumber of profiles
Profiles3 records
Neuronetics, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neuronetics, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neuronetics, Inc.
What does Neuronetics, Inc. do?
Neuronetics designs, manufactures, and markets the NeuroStar Advanced Therapy System, an FDA-cleared transcranial magnetic stimulation (TMS) platform that uses focused magnetic pulses to stimulate underactive neurons in mood-regulating regions of the brain. The system is sold to healthcare practices (psychiatry practices and mental health clinics) for treatment of Major Depressive Disorder in adults and adolescents (ages 15-21), OCD, and anxious depression. The company supports practices through its 5 STARS Solution program, providing implementation, training, marketing, and reimbursement assistance.
Is Neuronetics, Inc. a public or private company?
Neuronetics, Inc. is a public company. It is classified as public and is currently operating.
When was Neuronetics, Inc. founded?
Neuronetics, Inc. was founded in -1. It employs 101 to 250 people.
Where is Neuronetics, Inc. based?
Neuronetics, Inc. is headquartered in Malvern, United States, in the North America region.
How does Neuronetics, Inc. make money?
Two revenue lines are on record. NeuroStar TMS Device/System Sales are the primary driver. The others are treatment Services Reimbursement.
Who are Neuronetics, Inc.'s main competitors?
Direct peers on record are MagVenture, Magstim and Brainsway. Broad incumbents are Axsome Therapeutics, Janssen Pharmaceuticals (Johnson & Johnson) — Spravato and Sage Therapeutics. Emerging players are Compass Pathways, Neurosoft Bioelectronics and Fisher Wallace. Somatics LLC is listed as an others.
Does Neuronetics, Inc. have an API?
No public API is recorded for Neuronetics, Inc..
What industry is Neuronetics, Inc. in?
Neuronetics, Inc.'s product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.